绥美凯推荐用量是多少呢？

It is a compound preparation. Each tablet contains 50 mg of dolutegravir sodium (calculated as dolutegravir), 600 mg of abacavir sulfate (calculated as abacavir) and 300 mg of lamivudine. It is suitable for the treatment of adults infected with human immunodeficiency virus (HIV) and adolescents over 12 years old (with a weight of at least 40 kg). Since Trimicai was approved for marketing in 2014, it took only two years to top the global AIDS drug sales rankings. On January 20, 2018, GlaxoSmithKline China (GSK China) announced that its single-tablet compound preparation Trimicid (chemical name: doptabalamid tablets) was officially launched in mainland China. So what is the recommended dosage of Suimeikai?

dose

Adults and teenagers (weighing at least 40kg)

For adults and adolescents, the recommended dose of Trimax is one tablet once daily.

Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced.

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

Miss a dose

If the patient misses a dose of Suimei Kai and there are more than 4 hours before the next dose, Sui Meikai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

elderly patients

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

kidney damage

Patients whose creatinine clearance rate is less than 50mL/min are not recommended to take Suimeikai.

liver damage

Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment and therefore its use is not recommended unless deemed necessary. For patients with mild hepatic impairment, close monitoring is required, including monitoring of abacavir plasma levels when feasible.